Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study

Paparrigopoulos, Thomas; Tzavellas, Elias; Karaiskos, Dimitris; Kourlaba, Georgia; Liappas, Ioannis
January 2011
BMC Psychiatry;2011, Vol. 11 Issue 1, p41
Academic Journal
Background: GABAergic anticonvulsants have been recommended for the treatment of alcohol dependence and the prevention of relapse. Several studies have demonstrated topiramate's efficacy in improving drinking behaviour and maintaining abstinence. The objective of the present open-label controlled study was to assess efficacy and tolerability of low-dose topiramate as adjunctive treatment in alcohol dependence during the immediate postdetoxification period and during a 16-week follow-up period after alcohol withdrawal. Methods: Following a 7-10 day inpatient alcohol detoxification protocol, 90 patients were assigned to receive either topiramate (up to 75 mg per day) in addition to psychotherapeutic treatment (n = 30) or psychotherapy alone (n = 60). Symptoms of depression and anxiety, as well as craving, were monitored for 4-6 weeks immediately following detoxification on an inpatient basis. Thereafter, both groups were followed as outpatients at a weekly basis for another 4 months in order to monitor their course and abstinence from alcohol. Results: A marked improvement in depressive (p < 0.01), anxiety (p < 0.01), and obsessive-compulsive drinking symptoms (p < 0.01) was observed over the consecutive assessments in both study groups. However, individuals on topiramate fared better than controls (p < 0.01) during inpatient treatment. Moreover, during the 4-month follow up period, relapse rate was lower among patients who received topiramate (66.7%) compared to those who received no adjunctive treatment (85.5%), (p = 0.043). Time to relapse in the topiramate augmentation group was significantly longer compared to the control group (log rank test, p = 0.008). Thus, median duration of abstinence was 4 weeks for the non-medicated group whereas it reached 10 weeks for the topiramate group. No serious side effects of topiramate were recorded throughout the study. Conclusions: Low-dose topiramate as an adjunct to psychotherapeutic treatment is well tolerated and effective in reducing alcohol craving, as well as symptoms of depression and anxiety, present during the early phase of alcohol withdrawal. Furthermore, topiramate considerably helps to abstain from drinking during the first 16-week postdetoxification period.


Related Articles

  • Predictors of patient entry into alcohol treatment after initial diagnosis. Kirchner, JoAnn E.; Booth, Brenda M.; Owen, Richard R.; Lancaster, A. Elizabeth; Smith, G. Richard; Kirchner, J E; Booth, B M; Owen, R R; Lancaster, A E; Smith, G R // Journal of Behavioral Health Services & Research;Aug2000, Vol. 27 Issue 3, p339 

    To improve the quality of care for alcohol-related disorders, key transitions in the continuum of care, including treatment entry, must be fully understood. The purpose of this study was to investigate identifiable predictors of patient entry into a substance-use treatment program following the...

  • An overview of outpatient and inpatient detoxification. HAYASHIDA, MOTOI // Alcohol Health & Research World;1998, Vol. 22 Issue 1, p44 

    Describes the advantages and disadvantages of inpatient and outpatient alcohol detoxification programs and considers the influence that the detoxification setting may have on long-term treatment outcomes. Detoxification and overall treatment outcome; Transition from detoxification to...

  • A combination of carbamazepine/tiapride in outpatient alcohol detoxification: Results from an open clinical study. Soyka, Michael; Morhart-Klute, Veronika; Horak, Michael // European Archives of Psychiatry & Clinical Neuroscience;2002, Vol. 252 Issue 5, p197 

    This was an open, prospective study to examine the efficacy, practicability and medical safety of a combination of carbamazepine and tiapride in outpatient detoxification of alcohol-dependent patients. Patients were carefully screened for relevant neuropsychiatric disorders and then seen on a...

  • Management of Alcohol Withdrawal Syndrome. RICKS, JANET; REPLOGLE, WILLIAM H.; COOK, NAKIA JOYE // American Family Physician;8/15/2010, Vol. 82 Issue 4, p344 

    Answers to a question on which detoxification regimen is the most effective for people with alcohol withdrawal syndrome are presented.

  • Leptin Levels of Alcohol Abstainers and Detoxification Patients Are Not Different. Wurst, Friedrich Martin; Bechtel, Gaby; Forster, Stefan; Wolfersdorf, Manfred; Huber, Peter; Scholer, AndrĂ©; Pridzun, Lutz; Alt, Andreas; Seidl, Stephan; Dierkes, Jutta; Dammann, Gerhard // Alcohol & Alcoholism;Jul/Aug2003, Vol. 38 Issue 4, p364 

    Aims: Leptin is a cytokine-type peptide hormone, recently implicated as a putative state marker of alcohol use and in craving. Our goal was to evaluate the potential of leptin as a state and trait marker and to rule out the role of current alcohol intoxication on leptin levels. Methods: Eighteen...

  • TRAUMA LOAD PREDICTS FIRST TREATMENT IN LIFE AMONG ALCOHOL PATIENTS. Odenwald, M.; Steffen, F. // Canadian Journal of Addiction Medicine;Feb2013, Vol. 4 Issue 1, p10 

    An abstract of the article "Reducing Dropout among Traumatized Alcohol Patients in Detoxification Treatment," by M. Odenwald and P. Semrau is presented.

  • Where and when to detoxify single homeless drinkers. Haigh, Rex; Hibbert, George // BMJ: British Medical Journal (International Edition);10/13/90, Vol. 301 Issue 6756, p848 

    Compares the services offered between two alcohol units for the homeless persons in Oxford, England. Detoxification of the patients; Administration of drug treatment; Occurrence of macrocytosis in majority of the patients.

  • Prolonged Abstinence and Changes in Alcoholic Personality: A NEO PI-R Study. Boulze, Isabelle; Launay, Michel; Nalpas, Bertrand // Psychology (2152-7180);Mar2014, Vol. 5 Issue 4, p312 

    Many studies have examined the risk factors for relapse in alcohol-dependent patients within the first year of treatment, and have generally focused on two personality dimensions: emotional instability and difficulty in establishing relationships. In this study, we examine if these weaknesses...

  • Study ECG Effects in Alcoholic and Normals. Swathi, K.; Nasar Ahamed, R. // Journal of Pharmaceutical Sciences & Research;2014, Vol. 6 Issue 7, p263 

    Background: Alcohol is a cardiotoxin for over a hundred of years. The heavy alcohol consumption is associated with a type of non ischaemic dilated cardiomyopathy termed alcoholic cardiomyopathy. The prevalence of cardiac deceases and other electrocardiographic changes occurring in these clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics